Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

Oren Zimhony, Jeffery S. Cox, John T. Welch, Catherine Vilchèze, William R. Jacobs

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobocterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity. We have found that the eukaryotic-like fas 1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M. smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C(24/C26) fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.

Original languageEnglish (US)
Pages (from-to)1043-1047
Number of pages5
JournalNature Medicine
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2000

Fingerprint

Pyrazinamide
Fatty Acid Synthases
Mycobacterium tuberculosis
Pharmaceutical Preparations
Tuberculosis
Smegma
Multidrug-Resistant Tuberculosis
Acetyl Coenzyme A
Gene encoding
Biosynthesis
Isoniazid
Prodrugs
Rifampin
Mycobacterium
Mycobacterium bovis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. / Zimhony, Oren; Cox, Jeffery S.; Welch, John T.; Vilchèze, Catherine; Jacobs, William R.

In: Nature Medicine, Vol. 6, No. 9, 01.09.2000, p. 1043-1047.

Research output: Contribution to journalArticle

@article{64b34d23a1f240699c45133b3aa1a08d,
title = "Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis",
abstract = "Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobocterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity. We have found that the eukaryotic-like fas 1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M. smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C(24/C26) fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.",
author = "Oren Zimhony and Cox, {Jeffery S.} and Welch, {John T.} and Catherine Vilch{\`e}ze and Jacobs, {William R.}",
year = "2000",
month = "9",
day = "1",
doi = "10.1038/79558",
language = "English (US)",
volume = "6",
pages = "1043--1047",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

AU - Zimhony, Oren

AU - Cox, Jeffery S.

AU - Welch, John T.

AU - Vilchèze, Catherine

AU - Jacobs, William R.

PY - 2000/9/1

Y1 - 2000/9/1

N2 - Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobocterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity. We have found that the eukaryotic-like fas 1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M. smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C(24/C26) fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.

AB - Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobocterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity. We have found that the eukaryotic-like fas 1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M. smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C(24/C26) fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0033834868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033834868&partnerID=8YFLogxK

U2 - 10.1038/79558

DO - 10.1038/79558

M3 - Article

C2 - 10973326

AN - SCOPUS:0033834868

VL - 6

SP - 1043

EP - 1047

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -